Search
for
Sort by
Research 631–660 of 1000+
- Bone infarcts in a woman with systemic lupus erythematosus and antiphospholipid antibody syndrome
- Unraveling Translational Insights into Systemic Multi-Organ Toxicity of Cytosine Arabinoside (Ara-C): A Systematic Review of Preclinical Animal Evidence
- Testosterone: The Male Sex Hormone
- Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry—The European and North America Regulation Challenges
- PPAR-<i>γ</i> Agonists and Their Role in Primary Cicatricial Alopecia
- Use of platelet rich plasma for skin rejuvenation
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- 18β‐Glycyrrhetinic acid: its core biological properties and dermatological applications
- Overview of popular cosmeceuticals in dermatology
- Hair Disorders in Autoimmune Diseases
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Scaly Papular Lesions
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
- Anthelminthic drugs
- NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
- Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
- Imported cutaneous Leishmaniasis in Japan
- BH03: Systemic sclerosis and frontal fibrosing alopecia: a novel combination of scarring alopecia
- HAIR AND SYSTEMATIC DISEASE
- Soft Nails After Treatment With Aromatic Retinoids
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Idiopathic CD4+ T-lymphocytopenia
- Skin diseases in consequence of endocrine alterations
- Contact dermatitis to phenol‐formaldehyde resin in two plywood factory workers
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?